2024
Stiffening of the human proximal pulmonary artery with increasing age
Manning E, Mishall P, Ramachandra A, Hassab A, Lamy J, Peters D, Murphy T, Heerdt P, Singh I, Downie S, Choudhary G, Tellides G, Humphrey J. Stiffening of the human proximal pulmonary artery with increasing age. Physiological Reports 2024, 12: e16090. PMID: 38884325, PMCID: PMC11181131, DOI: 10.14814/phy2.16090.Peer-Reviewed Original ResearchConceptsProximal pulmonary arteriesPulmonary arteryAge-related stiffeningRight ventricular ejection fractionVentricular ejection fractionMean wall thicknessEjection fractionNo significant differenceSystemic circulationLuminal caliberDiffusing capacityArterial stiffeningIncreasing ageSignificant differenceDistensionArteryWall thicknessAdverse effectsWall strainVessel diameterCyclic biaxial strainOrgan donorsAgeMicrostructural remodeling
2018
Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers
Kaullen JD, Owen JS, Brouwer KLR, Heerdt PM, Lien CA, Savarese JJ, Schmith VD. Pharmacokinetic/Pharmacodynamic Model of CW002, an Investigational Intermediate Neuromuscular Blocking Agent, in Healthy Volunteers. Anesthesiology 2018, 128: 1107-1116. PMID: 29494403, PMCID: PMC5953789, DOI: 10.1097/aln.0000000000002157.Peer-Reviewed Original ResearchConceptsNeuromuscular blocking agentsBlocking agentRapid onsetPharmacodynamic modelDifferent dose cohortsMuscle twitch heightOffset of effectSingle ascending dosePharmacokinetic/Pharmacodynamic ModelArterial plasma concentrationsIntermediate durationPlasma drug concentration dataSigmoid Emax modelDose-response studyDrug concentration dataConcentration-time dataLow interindividual variabilityDose cohortsED95 dosesAscending dosePredictable pharmacokineticsSevoflurane anesthesiaPopulation pharmacokineticsSingle dosesTwitch height
2016
Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man
Heerdt PM, Sunaga H, Owen JS, Murrell MT, Malhotra JK, Godfrey D, Steinkamp M, Savard P, Savarese JJ, Lien CA. Dose–response and Cardiopulmonary Side Effects of the Novel Neuromuscular-blocking Drug CW002 in Man. Anesthesiology 2016, 125: 1136-1143. PMID: 27749289, DOI: 10.1097/aln.0000000000001386.Peer-Reviewed Original ResearchConceptsCardiopulmonary side effectsHistamine releaseSide effectsBlood pressureHealthy subjectsHeart rateSevoflurane/nitrous oxideDose-escalation clinical trialDynamic airway complianceNeuromuscular-blocking drugsEscalation clinical trialPlasma histamine concentrationSigmoid Emax modelClinical recoveryClinical durationAdductor pollicisTwitch depressionAirway complianceNeuromuscular blockadeClinical trialsPreclinical studiesArterial bloodEmax modelHistamine concentrationCW002
2015
Non-invasive cardiac output monitoring for cesarean delivery under epidural anesthesia in a patient with Marfan syndrome and cardiomyopathy
Beaudry S, Pick J, Heerdt P. Non-invasive cardiac output monitoring for cesarean delivery under epidural anesthesia in a patient with Marfan syndrome and cardiomyopathy. International Journal Of Obstetric Anesthesia 2015, 25: 82-85. PMID: 26718697, DOI: 10.1016/j.ijoa.2015.11.003.Peer-Reviewed Original ResearchConceptsNon-invasive cardiac output monitoringCardiac outputCardiac output monitoringCesarean deliveryStroke volumeEpidural anesthesiaBaseline valuesMarfan syndromeLeft ventricular ejection fractionOutput monitoringUse of phenylephrineEnd of surgeryIntravascular volume depletionMaternal cardiac outputMitral valve replacementSystemic blood pressureAdequate surgical anesthesiaClose hemodynamic monitoringVentricular ejection fractionAcute blood lossAcute volume overloadStroke volume increaseValve replacementBlood lossBlood pressure
2006
Cardiomyopathic Etiology and SERCA2a Reverse Remodeling During Mechanical Support of the Failing Human Heart
Heerdt PM, Klotz S, Burkhoff D. Cardiomyopathic Etiology and SERCA2a Reverse Remodeling During Mechanical Support of the Failing Human Heart. Anesthesia & Analgesia 2006, 102: 32-37. PMID: 16368801, DOI: 10.1213/01.ane.0000183642.09435.ad.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceAnimalsBiomechanical PhenomenaCalcium-Transporting ATPasesCardiomyopathy, DilatedConfidence IntervalsDatabases, FactualFemaleGene Expression Regulation, EnzymologicHeart-Assist DevicesHumansIn Vitro TechniquesMaleMiddle AgedRatsSarcoplasmic Reticulum Calcium-Transporting ATPasesVentricular RemodelingConceptsLeft ventricular assist deviceForce-frequency relationshipSERCA2a functionMyocardial force-frequency relationshipMyocyte calcium cyclingSERCA2a gene expressionFailing Human HeartVentricular assist deviceChronic failureProportion of trabeculaeReverse remodelingLVAD supportMyopathic originSubtype 2aDCM heartsDisease processSERCA2a mRNAAssist deviceCalcium cyclingHeart samplesAbnormal expressionMyocardial trabeculaeGene expressionMolecular remodelingHuman heart
2002
Disease-specific remodeling of cardiac mitochondria after a left ventricular assist device
Heerdt PM, Schlame M, Jehle R, Barbone A, Burkhoff D, Blanck TJ. Disease-specific remodeling of cardiac mitochondria after a left ventricular assist device. The Annals Of Thoracic Surgery 2002, 73: 1216-1221. PMID: 11996266, DOI: 10.1016/s0003-4975(01)03621-9.Peer-Reviewed Original Research